MX2009000709A
(es)
|
2006-07-18 |
2009-02-04 |
Sanofi Aventis |
Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
PL2019104T3
(pl)
*
|
2007-07-19 |
2014-03-31 |
Sanofi Sa |
Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne
|
GB0819097D0
(en)
*
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
ES2604668T3
(es)
|
2009-02-05 |
2017-03-08 |
Immunogen, Inc. |
Nuevos derivados de benzodiacepina
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
FR2949469A1
(fr)
*
|
2009-08-25 |
2011-03-04 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application en therapeutique
|
TW201116297A
(en)
|
2009-10-02 |
2011-05-16 |
Sanofi Aventis |
Antibodies that specifically bind to the EphA2 receptor
|
WO2011100403A1
(en)
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc |
Cd20 antibodies and uses thereof
|
US8697688B2
(en)
|
2010-04-15 |
2014-04-15 |
Seattle Genetics Inc. |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
MA34277B1
(fr)
*
|
2010-04-15 |
2013-06-01 |
Spirogen Developments Sarl |
Pyrrolobenzodiazépines et conjugués de celles-ci
|
BR112012026801B8
(pt)
|
2010-04-15 |
2021-05-25 |
Medimmune Ltd |
conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento
|
FR2963007B1
(fr)
*
|
2010-07-26 |
2013-04-05 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application therapeutique
|
KR20190089048A
(ko)
|
2011-02-15 |
2019-07-29 |
이뮤노젠 아이엔씨 |
컨쥬게이트의 제조방법
|
US9156854B2
(en)
|
2011-04-18 |
2015-10-13 |
Immunogen, Inc. |
Maytansinoid derivatives with sulfoxide linker
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
MX341524B
(es)
|
2011-09-20 |
2016-08-24 |
Medimmune Ltd |
Pirrolobenzodiazepinas como compuestos pbd dimericos asimetricos para inclusion en conjugados dirigidos.
|
EP2751111B1
(en)
|
2011-10-14 |
2017-04-26 |
MedImmune Limited |
Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
|
WO2013053871A1
(en)
|
2011-10-14 |
2013-04-18 |
Spirogen Sàrl |
Pyrrolobenzodiazepines
|
WO2013055990A1
(en)
|
2011-10-14 |
2013-04-18 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
ES2556584T3
(es)
*
|
2011-10-14 |
2016-01-19 |
Medimmune Limited |
Pirrolobenzodiazepinas y conjugados de las mismas
|
CN103997893B
(zh)
|
2011-10-14 |
2019-04-12 |
西雅图基因公司 |
吡咯并苯并二氮杂卓和靶向结合物
|
EP3539985A1
(en)
|
2012-02-24 |
2019-09-18 |
AbbVie Stemcentrx LLC |
Anti sez6 antibodies and methods of use
|
EP3093294A1
(en)
|
2012-02-24 |
2016-11-16 |
Stemcentrx, Inc. |
Dll3 modulators and methods of use
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US9056910B2
(en)
|
2012-05-01 |
2015-06-16 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
CA3131619A1
(en)
|
2012-05-15 |
2013-11-21 |
Seagen Inc. |
Self-stabilizing linker conjugates
|
WO2013177481A1
(en)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazepines and conjugates thereof
|
EA201590174A1
(ru)
|
2012-07-09 |
2015-09-30 |
Дженентек, Инк. |
Иммуноконъюгаты, содержащие анти-cd22 антитела
|
US20140030280A1
(en)
|
2012-07-09 |
2014-01-30 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates
|
CN104717979A
(zh)
|
2012-08-02 |
2015-06-17 |
基因泰克公司 |
抗etbr抗体和免疫偶联物
|
WO2014031566A1
(en)
|
2012-08-22 |
2014-02-27 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
US9745303B2
(en)
|
2012-10-12 |
2017-08-29 |
Medimmune Limited |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
DK2906296T3
(en)
|
2012-10-12 |
2018-05-22 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
PL2906298T3
(pl)
|
2012-10-12 |
2019-04-30 |
Adc Therapeutics Sa |
Koniugaty pirolobenzodiazepina - przeciwciało
|
PT2906251T
(pt)
|
2012-10-12 |
2017-12-04 |
Medimmune Ltd |
Conjugados de pirrolobenzodiazepina-anticorpo anti-cd22
|
WO2014057074A1
(en)
|
2012-10-12 |
2014-04-17 |
Spirogen Sàrl |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2014057120A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
ES2680153T3
(es)
|
2012-10-12 |
2018-09-04 |
Adc Therapeutics Sa |
Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
|
LT2906253T
(lt)
|
2012-10-12 |
2018-10-10 |
Adc Therapeutics Sa |
Pirolobenzodiazepino-anti-psma antikūno konjugatas
|
TR201902494T4
(tr)
|
2012-10-12 |
2019-03-21 |
Medimmune Ltd |
Pirrolobenzodiazepinler ve onların konjugatları.
|
CN105849086B
(zh)
|
2012-11-24 |
2018-07-31 |
杭州多禧生物科技有限公司 |
亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
|
CN110627797A
(zh)
|
2012-12-21 |
2019-12-31 |
麦迪穆有限责任公司 |
用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
|
EA031585B1
(ru)
|
2012-12-21 |
2019-01-31 |
Медимьюн Лимитед |
Пирролобензодиазепины и их конъюгаты
|
EP2745876A1
(en)
|
2012-12-21 |
2014-06-25 |
Prous Institute for Biomedical Research, S.A. |
Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives
|
PL2958944T3
(pl)
|
2013-02-22 |
2019-09-30 |
Abbvie Stemcentrx Llc |
Koniugaty przeciwciało anty-DLL3-PBD i ich zastosowania
|
CN105209077B
(zh)
|
2013-03-13 |
2019-06-11 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓以及其结合物
|
EA027910B1
(ru)
|
2013-03-13 |
2017-09-29 |
Медимьюн Лимитед |
Пирролобензодиазепины и их конъюгаты
|
CN105142674B
(zh)
|
2013-03-13 |
2018-11-13 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓和其结合物
|
MX2015010777A
(es)
|
2013-03-14 |
2016-04-25 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-b7-h4.
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
CN105636612B
(zh)
|
2013-08-12 |
2020-01-14 |
基因泰克公司 |
抗体-药物缀合物及使用和治疗方法
|
ES2871418T3
(es)
|
2013-08-28 |
2021-10-28 |
Abbvie Stemcentrx Llc |
Composiciones y métodos de conjugación de anticuerpos específicos de sitio
|
EP3338793A1
(en)
|
2013-08-28 |
2018-06-27 |
AbbVie Stemcentrx LLC |
Novel sez6 modulators and methods of use
|
JP6332773B2
(ja)
*
|
2013-09-02 |
2018-05-30 |
ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. |
薬物と細胞結合分子との共役のための新規細胞毒性分子
|
KR20160055252A
(ko)
|
2013-09-17 |
2016-05-17 |
제넨테크, 인크. |
항-lgr5 항체의 사용 방법
|
WO2015052534A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
EP3054983B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
EP3054986B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
MX2021008464A
(es)
|
2013-10-15 |
2023-03-03 |
Seattle Genetics Inc |
Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
|
AU2014346792A1
(en)
|
2013-11-06 |
2016-06-02 |
Abbvie Stemcentrx Llc |
Novel anti-claudin antibodies and methods of use
|
BR112016013048A2
(pt)
|
2013-12-12 |
2017-09-26 |
Stemcentrx Inc |
anticorpos anti-dpep3 e métodos de uso
|
EP3461845B1
(en)
|
2013-12-13 |
2020-09-16 |
Genentech, Inc. |
Anti-cd33 antibodies and immunoconjugates
|
BR112016013258A2
(pt)
|
2013-12-16 |
2018-01-16 |
Genentech Inc |
composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
|
KR102532137B1
(ko)
|
2014-02-11 |
2023-05-12 |
씨젠 인크. |
단백질의 선택적 환원
|
PE20161209A1
(es)
|
2014-02-21 |
2016-11-10 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
|
CN114262344A
(zh)
|
2014-02-28 |
2022-04-01 |
杭州多禧生物科技有限公司 |
带电荷链接体及其在共轭反应上的应用
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
GB201407816D0
(en)
|
2014-05-02 |
2014-06-18 |
King S College London |
Pyrrolobenzodiazepine Compounds
|
CA2946662A1
(en)
|
2014-05-22 |
2015-11-26 |
Genentech, Inc. |
Anti-gpc3 antibodies and immunoconjugates
|
WO2016008112A1
(en)
|
2014-07-16 |
2016-01-21 |
Medshine Discovery Inc. |
Linkers and application towards adc thereof
|
KR20230172625A
(ko)
|
2014-08-28 |
2023-12-22 |
바이오아트라, 인코퍼레이티드 |
변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
|
SG11201701328XA
(en)
*
|
2014-09-02 |
2017-03-30 |
Immunogen Inc |
Methods for formulating antibody drug conjugate compositions
|
US9381256B2
(en)
|
2014-09-03 |
2016-07-05 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
HUE051002T2
(hu)
|
2014-09-03 |
2021-01-28 |
Immunogen Inc |
Citotoxikus benzodiazepin származékok
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗mfi2抗體及使用方法
|
EP3193940A1
(en)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
ES2989338T3
(es)
|
2014-09-12 |
2024-11-26 |
Genentech Inc |
Anticuerpos anti CLL-1 e inmunoconjugados
|
EP3191135B1
(en)
|
2014-09-12 |
2020-08-19 |
Genentech, Inc. |
Anti-her2 antibodies and immunoconjugates
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
EP3191518B1
(en)
|
2014-09-12 |
2020-01-15 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
TW201625688A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
經半胱胺酸改造之抗體及接合物
|
JP6730261B2
(ja)
*
|
2014-09-17 |
2020-07-29 |
ジェネンテック, インコーポレイテッド |
抗her2抗体を含む免疫複合体
|
CN107073136A
(zh)
|
2014-09-17 |
2017-08-18 |
健泰科生物技术公司 |
吡咯并苯并二氮杂卓及其抗体二硫化物偶联物
|
KR20170101895A
(ko)
|
2014-11-25 |
2017-09-06 |
에이디씨 테라퓨틱스 에스에이 |
피롤로벤조디아제핀-항체 접합체
|
CN107231804B
(zh)
|
2015-01-14 |
2019-11-26 |
百时美施贵宝公司 |
亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
|
EP3245213B1
(en)
|
2015-01-14 |
2020-03-04 |
Bristol-Myers Squibb Company |
Benzodiazepine dimers, conjugates thereof, and methods of making and using
|
US9504694B2
(en)
|
2015-03-19 |
2016-11-29 |
Cellerant Therapeutics, Inc. |
Isoquinolidinobenzodiazepines
|
MX2017012982A
(es)
|
2015-04-10 |
2018-07-06 |
Univ Jefferson |
Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
EA201792516A1
(ru)
|
2015-06-23 |
2018-05-31 |
Бристол-Маерс Сквибб Компани |
Макроциклические димеры бензодиазепина, их конъюгаты, получение и применение
|
EP3319936A4
(en)
|
2015-07-12 |
2019-02-06 |
Suzhou M-conj Biotech Co., Ltd. |
BRIDGE LINKER FOR CONJUGATING CELL BINDING MOLECULES
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
RS59806B1
(sr)
|
2015-07-21 |
2020-02-28 |
Immunogen Inc |
Postupci za pripremu citotoksičnih benzodiazepinskih derivata
|
EP4477269A3
(en)
|
2015-09-20 |
2025-03-19 |
The United States of America, as Represented By the Secretary, Department of Health and Human Services |
Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
KR102626498B1
(ko)
|
2016-03-25 |
2024-01-19 |
씨젠 인크. |
페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
KR102459684B1
(ko)
|
2016-04-15 |
2022-10-26 |
바이오아트라, 인코퍼레이티드 |
항 Axl항체 및 이의 면역접합체와 이것들의 용도
|
CA3021098A1
(en)
|
2016-04-21 |
2017-10-26 |
Abbvie Stemcentrx Llc |
Novel anti-bmpr1b antibodies and methods of use
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
WO2017194568A1
(en)
|
2016-05-11 |
2017-11-16 |
Sanofi |
Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
|
KR20180137517A
(ko)
|
2016-05-13 |
2018-12-27 |
바이오아트라, 엘엘씨 |
항 ror2 항체, 항체 단편 및 이의 면역접합체와 이것들의 용도
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
WO2018026533A1
(en)
|
2016-08-02 |
2018-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
|
KR20190038579A
(ko)
|
2016-08-09 |
2019-04-08 |
시애틀 지네틱스, 인크. |
개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
KR102459468B1
(ko)
|
2016-11-14 |
2022-10-26 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
AU2017361887B2
(en)
|
2016-11-21 |
2019-08-15 |
Cureab Gmbh |
Anti-GP73 antibodies and immunoconjugates
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
CA3045902A1
(en)
|
2016-12-21 |
2018-06-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for flt3 and uses thereof
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
CA3047683C
(en)
|
2017-02-08 |
2020-03-10 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
HRP20211640T1
(hr)
|
2017-02-08 |
2022-02-04 |
Adc Therapeutics Sa |
Konjugati pirolobenzodiazepin - protutijelo
|
SG11201908325PA
(en)
|
2017-03-24 |
2019-10-30 |
Seattle Genetics Inc |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
AU2018255876B2
(en)
|
2017-04-18 |
2020-04-30 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
US20200129637A1
(en)
|
2017-04-20 |
2020-04-30 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
WO2018195243A1
(en)
|
2017-04-20 |
2018-10-25 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives and conjugates thereof
|
US11389480B2
(en)
|
2017-05-19 |
2022-07-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
|
UA127900C2
(uk)
|
2017-06-14 |
2024-02-07 |
Ейдісі Терапьютікс Са |
Схема дозування для введення adc до cd19
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
CA3070446A1
(en)
|
2017-07-25 |
2019-01-31 |
Immutics, Inc. |
Treating cancer by blocking the interaction of tim-3 and its ligand
|
EP3668874B1
(en)
|
2017-08-18 |
2021-12-22 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
AU2018337815A1
(en)
|
2017-09-20 |
2020-03-12 |
Ph Pharma Co., Ltd. |
Thailanstatin analogs
|
CN116999573A
(zh)
|
2017-09-29 |
2023-11-07 |
第一三共株式会社 |
抗体-药物偶联物及其制造方法、药物组合物及其在制备治疗肿瘤的药物中的应用
|
CN111542511A
(zh)
*
|
2017-11-02 |
2020-08-14 |
宇部兴产株式会社 |
蛋白分解酶的双头型抑制剂
|
EP3710066B1
(en)
|
2017-11-14 |
2022-06-08 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
JP2021508714A
(ja)
|
2017-12-28 |
2021-03-11 |
イミュノジェン・インコーポレーテッド |
ベンゾジアゼピン誘導体
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
CN112203696A
(zh)
|
2018-05-25 |
2021-01-08 |
免疫医疗有限公司 |
吡咯并苯并二氮杂*缀合物
|
AU2019301675A1
(en)
|
2018-07-12 |
2021-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured CD22-specific monoclonal antibody and uses thereof
|
WO2020025108A1
(en)
|
2018-07-31 |
2020-02-06 |
Astrazeneca Ab |
Linkers and conjugates
|
CN112585163B
(zh)
|
2018-08-08 |
2025-03-25 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向磷脂酰肌醇蛋白聚糖-2的高亲和力单克隆抗体及其用途
|
CA3112977A1
(en)
|
2018-10-19 |
2020-04-23 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
KR20210081350A
(ko)
|
2018-10-19 |
2021-07-01 |
메드임뮨 리미티드 |
피롤로벤조디아제핀 컨쥬게이트
|
EP3899048A1
(en)
|
2018-12-19 |
2021-10-27 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine resistance
|
GB201820725D0
(en)
|
2018-12-19 |
2019-01-30 |
Adc Therapeutics Sarl |
Pyrrolobenzodiazepine resistance
|
JP2022513482A
(ja)
|
2018-12-21 |
2022-02-08 |
アビディティー バイオサイエンシーズ,インク. |
抗トランスフェリン受容体抗体およびその使用
|
US20220096641A1
(en)
*
|
2019-01-03 |
2022-03-31 |
Legochem Biosciences, Inc. |
Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
|
EP3883608A1
(en)
|
2019-01-08 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
WO2020154150A1
(en)
|
2019-01-22 |
2020-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
CA3127113A1
(en)
|
2019-01-30 |
2020-08-06 |
Dongxu Sun |
Anti-gal3 antibodies and uses thereof
|
BR112021018260A2
(pt)
|
2019-03-15 |
2021-11-23 |
Medimmune Ltd |
Dímeros de azetidobenzodiazepina e conjugados compreendendo-os para uso no tratamento de câncer
|
CN118221763A
(zh)
|
2019-03-29 |
2024-06-21 |
免疫医疗有限公司 |
化合物及其缀合物
|
TW202102506A
(zh)
|
2019-03-29 |
2021-01-16 |
美商伊繆諾金公司 |
苯二氮平衍生物
|
GB201908128D0
(en)
|
2019-06-07 |
2019-07-24 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
CN110483504B
(zh)
*
|
2019-08-02 |
2022-04-26 |
桂林理工大学 |
以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法
|
EP4045511A1
(en)
*
|
2019-10-16 |
2022-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Visual detection of pbd induced dna crosslinks
|
AU2020370125A1
(en)
|
2019-10-22 |
2022-05-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting B7H3 (CD276) for treating multiple solid tumors
|
WO2021080608A1
(en)
|
2019-10-25 |
2021-04-29 |
Medimmune, Llc |
Branched moiety for use in conjugates
|
CA3161573A1
(en)
|
2019-12-12 |
2021-06-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates specific for cd276 and uses thereof
|
WO2021148500A1
(en)
|
2020-01-22 |
2021-07-29 |
Medimmune Limited |
Compounds and conjugates thereof
|
TW202140076A
(zh)
|
2020-01-22 |
2021-11-01 |
英商梅迪繆思有限公司 |
化合物及其軛合物
|
CN115666589A
(zh)
|
2020-03-19 |
2023-01-31 |
艾维迪提生物科学公司 |
治疗面肩肱型肌营养不良的组合物和方法
|
BR112022019137A2
(pt)
|
2020-03-27 |
2023-01-31 |
Avidity Biosciences Inc |
Composições e métodos de tratamento de distrofia muscular
|
IL297167A
(en)
|
2020-04-10 |
2022-12-01 |
Seagen Inc |
Charging variant connectors
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
JP2024510435A
(ja)
|
2021-03-18 |
2024-03-07 |
シージェン インコーポレイテッド |
生体活性化合物の内部移行複合体からの選択的薬物放出
|
EP4308171A1
(en)
|
2021-03-18 |
2024-01-24 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
GB202105187D0
(en)
|
2021-04-12 |
2021-05-26 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
GB202105186D0
(en)
|
2021-04-12 |
2021-05-26 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
WO2022261017A1
(en)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
JP2024526764A
(ja)
|
2021-07-13 |
2024-07-19 |
トゥルーバインディング,インコーポレイテッド |
タンパク質凝集を防止する方法
|
GB202110726D0
(en)
|
2021-07-26 |
2021-09-08 |
Cambridge Entpr Ltd |
Conjugating reagents and conjugates thereof
|
AU2022345098A1
(en)
|
2021-09-16 |
2024-04-04 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
CN118524852A
(zh)
|
2021-11-09 |
2024-08-20 |
真和制药有限公司 |
治疗或抑制心血管疾病的方法
|
EP4519322A1
(en)
|
2022-05-03 |
2025-03-12 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
GB202207691D0
(en)
|
2022-05-25 |
2022-07-06 |
Cambridge Entpr Ltd |
Quinone protected forms and conjugates
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
WO2025019228A1
(en)
|
2023-07-20 |
2025-01-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
|
EP4509142A1
(en)
|
2023-08-16 |
2025-02-19 |
Ona Therapeutics S.L. |
Fgfr4 as target in cancer treatment
|